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BACKGROUND: Letrozole is the third-generation aromatase inhibitor (AI) most widely used in assisted reproduc-
tion. AIs induce ovulation by inhibiting estrogen production; the consequent hypoestrogenic state increases GnRH
release and pituitary follicle-stimulating hormone (FSH) synthesis. METHODS: A systematic search of the literature
was performed for both prospective and retrospective studies. Meta-analyses of randomized clinical trials (RCTs)
were performed for three comparisons: letrozole versus clomiphene citrate (CC), letrozole 1 FSH versus FSH in
intrauterine insemination (IUI) and letrozole 1 FSH versus FSH in IVF. In the absence of RCTs, non-randomized
studies were pooled. RESULTS: Nine studies were included in the meta-analysis. Four RCTs compared the overall
effect of letrozole with CC in patients with polycystic ovary syndrome. The pooled result was not signiﬁcant for ovu-
latory cycles (OR 5 1.17; 95% CI 0.66–2.09), or for pregnancy rate per cycle (OR 5 1.47; 95% CI 0.73–2.96) or for
pregnancy rate per patient (OR 5 1.37; 95% CI 0.70–2.71). In three retrospective studies which compared L 1 FSH
with FSH in ovarian stimulation for IUI, the pooled OR was 1.15 (95% CI 0.7821.71). A ﬁnal meta-analysis included
one RCT and one cohort study that compared letrozole 1 gonadotrophin versus gonadotrophin alone: the pooled
pregnancy rate per patient was not signiﬁcantly different (OR 5 1.40; 95% CI 0.67–2.91). CONCLUSIONS: Letro-
zole is as effective as other methods of ovulation induction. Further randomized-controlled studies are warranted to
deﬁne more clearly the efﬁcacy and safety of letrozole in human reproduction.
Keywords: androgens; FSH; IVF
Introduction
Ovulation induction regimens are widely used in assisted repro-
duction techniques to treat infertility. Pulsatile administration of
GnRH was established as an effective and safe means of treating
hypogonadotrophic hypogonadal women (WHO class I) (The
ESHRE Capri Workshop Group, 1995). However, in patients
with chronic anovulation who have adequate serum estrogen
levels, and follicle-stimulating hormone (FSH) and prolactin
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chemical hyperandrogenism (WHO class II), one therapeutic
option would be to block estrogen action at the central level.
Clomiphene citrate (CC) is a non-steroidal selective estrogen
receptor modulator, which acts primarily by binding with estrogen
receptors at the hypothalamus (Kurl and Morris, 1978). This com-
petitive inhibition results in a perceived drop of circulating estro-
gen to the hypothalamus, eventually leading to increased
gonadotrophin secretion and subsequent induction of ovulation
(Kerin et al., 1985). Augmenting endogenous FSH with CC treat-
ment is associated with a risk of ovarian hyperstimulation syn-
drome and multiple gestations (Fisher et al., 2002). Although
CC results in ovulation in most patients, the pregnancy rates are
disappointing. This has been attributed to its peripheral antiestro-
genic effects, mainly on the quality or quantity of cervical mucus,
and endometrial growth and maturation (Fritz et al., 1991) that
could prevent pregnancy in the face of successfully induced ovu-
lation. Long-lasting estrogen receptor depletion has been involved
in the antiestrogenic mechanism of action of CC. It also appears
that CC accumulates in the body because of its long half-life.
Because of these problems, the concept of aromatase inhibition
was proposed as a new method of ovulation induction that could
avoid many of the adverse effects of CC (Mitwally and Casper,
2000).
Aromatase is a microsomal member of the cytochrome
P450 hemoprotein-containing enzyme complex superfamily
(P450arom, the product of the CYP19 gene) that synthesizes estro-
gens by catalyzing three consecutive hydroxylation reactions con-
verting C19 androgens to aromatic C18 estrogenic steroids.
Aromatase converts androstenedione to estrone and testosterone
to estradiol. Its activity can be demonstrated in several tissues,
including the ovaries, brain, placenta, adipose tissue, muscle,
liver, breast and estrogen-dependent breast cancer. Aromatase is
expressed in a tissue-speciﬁc manner. This enzyme is mainly
expressed in the ovaries of premenopausal women. A very high
level of aromatase is expressed in placenta in pregnant women.
In post-menopausal women, the main source of estrogens is the
adipose tissue (Cole and Robinson, 1990).
Estradiol is produced by the ovarian granulosa cells and exerts a
negative feedback effect on FSH release from the pituitary gland.
When aromatization of androgens to estrogens is inhibited, a
reduction of circulating estrogens causes modiﬁcations in the
hypothalamic–pituitary–ovary axis, including:
(i) release of the hypothalamic–pituitary axis from estro-
genic negative feedback and FSH secretion is increased,
with the resultant stimulating effect on the growth of
ovarian follicles.
(ii) increase of intraovarian androgens secondary to aromatase
inhibition. A transient androgenic environment due to
relatively short half-life ( 45 h) seems to augment fol-
licular sensitivity to FSH. The concept that androgens
actually enhance early follicular growth is becoming
increasingly important (Weil et al., 1998).
(iii) aromatase inhibitors (AIs) do not antagonized estrogen
receptors in the brain and, therefore, feedback central
mechanisms remain intact. The initiation of follicle
growth accompanied by increasing concentrations of
estrogens results in normal negative feedback loop that
limits FSH response and atresia of small follicles, gener-
ally leading to mono-ovulatory cycles (Casper and
Mitwally, 2006).
The third-generation AIs include two non-steroidal inhibitors,
anastrozole and letrozole, and a steroidal agent, exemestane. Ana-
strozole and letrozole are selective AIs. They are reversible and
highly potent. These agents have been used as an adjunct treatment
for breast cancer in post-menopausal women. First-generation
(aminoglutethimide) and second-generation (fadrozol and formes-
tane) AIs are no longer used because of problems caused by their
low potency, lack of speciﬁcity and side effects, especially with
aminoglutethimide (Holzer et al., 2006). Conclusive data regard-
ing the optimal doses of AIs in reproductive medicine are
lacking. In most studies, letrozole has been administered at once-
daily doses of 2.5–5 mg for 5 days. Higher doses are associated
with a persistent inhibition of aromatase and a very low estrogen
levels to ensure an adequate endometrial growth at the time of
ovulation. In the case of anastrozole, sufﬁcient data to determine
the optimal dose are not available, although the recommended
daily dose of 1 mg in patients with hormone-sensitive breast
cancer may be adequate to achieve correct follicular growth
(Miller et al., 2000; Holzer et al., 2006).
In in vitro studies, letrozole showed the lowest IC50 and the
greatest relative potency, which indicates a higher in vitro inhibi-
tory effect on the enzyme aromatase (Bhatnagar et al., 1990).
Human pharmacodynamic studies demonstrated that letrozole
reduced speciﬁcally and markedly plasma concentrations of estra-
diol, estrone and estrone sulfate. The administration of this drug,
however, had no effect on plasma levels of other steroidal hor-
mones, so that concomitant treatment with corticosteroids or
mineralocorticoids is not needed. In none of the studies, treatment
with letrozole caused accumulation of androgens, androgen pre-
cursors, luteinizing hormone (LH), FSH, thyroid-stimulating
hormone (TSH) or renin. Letrozole showed a higher potency in
the inhibition of aromatization and distribution of estrogen
plasma levels than anastrozole (Bhatnagar et al., 1990).
Following the administration of a single oral dose of letrozole
2.5 mg to healthy subjects, the drug was completely and rapidly
absorbed from the gastrointestinal tract, reaching maximum
plasmaconcentrations about1 hafterdosing.Theextentofabsorp-
tion is not signiﬁcantly affected by food; therefore, letrozole may
betakenwithorwithoutfood.Letrozoleshowedrapidlyandexten-
sively distribution into peripheral tissues. A daily dose of 2.5 mg
achieved an apparent stable distribution volume of 1.9 l/kg. In
plasma, 60% of letrozole was weakly bound to proteins, mostly
albumin. The major route of elimination is via hepatic metabolism
to a pharmacologically inactive carbinol metabolite. The drug is
excreted mainly via the kidneys. After administration of 2.5 mg
14C-labeled letrozole,  90% ofradiolabeled letrozole isrecovered
in urine and only 4% in feces. Of letrozole recovered in urine,
.65% corresponds to the glucuronide conjugate of carbinol, 9%
to two unidentiﬁed metabolites and 5% to unchanged letrozole.
Letrozole terminal elimination half-life is about 2 days and
steady-state plasma concentration after daily 2.5 mg dosing is
reached in 2–6 weeks (Bhatnagar et al., 1990).
In the populations studied (adults between 35 and 80 years of
age), changes of pharmacokinetic parameters according to age
were not observed. In patients with renal insufﬁciency, with
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572renal clearance .10 ml/min, or in patients with mild to moderate
liver dysfunction, dose adjustments of letrozole were not required
(Bhatnagar et al., 1990).
Side effects from letrozole are uncommon and related to sup-
pression of the production of estrogens as a result of aromatase
inhibition induced by the drug. Side effects include hot ﬂashes
(11%), nausea (7%), fatigue (5%), alopecia and vaginal bleeding,
which occur more frequently in breast cancer patients than in
women treated for ovulation induction due to differences in the
duration of treatment. Finally, administration of cimetidine had
no effect on pharmacokinetics of letrozole, and letrozole had no
effect on pharmacokinetics of warfarin. However, co-adminis-
tration with taxoxifen leads to a signiﬁcant decrease in letrozole
plasma levels.
ItwaspostulatedthatitmaybepossibletomimictheactionofCC
withoutdepletionofestrogenreceptorsbyadministrationofanAIin
the early part of the menstrual cycle. Aromatase P450 is an enzyme
that catalyzes the production of estrogens (i.e. the conversion of
androstenedione and testosterone to estrone and estradiol, respect-
ively). Aromatase is a good target for selective inhibition because
estrogen production is a terminal step in the biosynthetic sequence.
Inhibition of aromatization will block estrogen production from all
sources and release the hypothalamic/pituitary axis fromestrogenic
negativefeedback.Theresultantincreaseingonadotrophinsecretion
willstimulategrowthofovarianfollicles.BecauseAIsdonotdeplete
estrogenreceptors,asdoesCC,normalcentralfeedbackmechanisms
remainintact.Asthedominantfolliclegrowsandestrogenlevelsrise,
normal negative feedback occurs centrally, resulting in suppression
of FSH and atresia of the smaller growing follicles. A single domi-
nant follicle, and mono-ovulation, should occur in most cases
(Casper and Mitwally, 2006).
This interesting therapeutic conception based on the mechanism
of action of AIs may be refuted by arguing that selective inhibition
of aromatase could result in temporary accumulation of intra-
ovarian androgens because conversion of androgen substrate to
estrogen is blocked by aromatase inhibition, which in turn may
be particularly deleterious for women with polycystic ovary syn-
drome (PCOS). However, studies of ovarian follicular develop-
ment in primates support a stimulatory role for androgens in
early follicular growth (Weil et al., 1998). Testosterone was
found to augment follicular FSH receptor expression, suggesting
that androgens promote follicular growth and estrogen biosyn-
thesis indirectly by amplifying FSH effects (Weil et al., 1999).
It is likely that women with PCOS already have a relative
aromatase deﬁciency in the ovary, leading to increased intraovar-
ian androgens, which leads to the development of multiple small
follicles responsible for the polycystic morphology of the
ovaries. The androgens may also increase FSH receptors making
women with PCOS exquisitely sensitive to an increase in FSH
through exogenous administration of gonadotrophins, and hence
the high risk of ovarian hyperstimulation syndrome and multiple
ovulation (Vendola et al., 1998).
As a result of the mechanisms of action described above, AIs
appear as new drugs to induce ovulation in women with normal
or increased levels of endogenous estrogens, such as those with
PCOS which constitute the largest group of anovulatory patients.
The lack of antiestrogenic effect is another interesting character-
istic of the mechanism of action of AIs, thus avoiding cervical
mucus and endometrial morphology interaction. AIs do not have
androgenic, progestagenic or estrogenic activity (Fatemi et al.,
2003).The use of AIs represents an important conceptual change
in the area of reproductive medicine and offers an interesting
therapeutic strategy based on the physiology of the normal ovula-
tory cycle, which has always been a primary aim for researchers
(Guzick, 2007; Wu et al., 2007). Moreover, clinical studies of
AIs for ovarian stimulation in IVF have shown that AIs could be
a low-cost alternative to natural-cycle IVF in patients who are
poor responders to FSH (Goswami et al., 2004; Schoolcraft
et al., 2004; Verpoest et al., 2006).
Although AIs offer a reasonably promising, effective and safe
option for ovulation induction as single agents or in combination
with FSH for assisted reproduction procedures, results of clinical
series should be assessed with caution due to limitations related
to the small sample sizes and heterogeneity of diseases, which
do not allow to draw ﬁrm conclusions of the efﬁcacy of these
agents. Data of a recent study suggest that the alert of a higher
risk of congenital cardiac and skeletal malformations in the new-
borns conceived after infertility treatment with the AI, letrozole,
seems unfounded (Tulandi et al., 2006). Challenging aspects of
this new concept of oral ovulation induction open a new era of
treatment of infertility in reproductive medicine.
The objective of this review is to provide current data of clinical
interest in the following areas: (i) use of letrozole in PCOS,
(ii) letrozole plus gonadotrophins in ovarian stimulation for intrau-
terine insemination (IUI), (iii) letrozole for IVF, (iv) use of letro-
zole for fertility preservation in oncological patients and (v) safety
proﬁle of AIs in ovulation induction. Besides a narrative descrip-
tion of clinically relevant data, a systematic review methodology
was adopted and three meta-analyses (letrozole versus clomiphene
in PCOS; letrozole combined with FSH versus FSH alone in
ovarian stimulation for IUI and letrozole combined with FSH
versus FSH alone for IVF) were performed.
Materials and Methods
We identiﬁed all English language medical papers published by means
of the PubMed electronic database using the following search terms:
letrozole, aromatase inhibitors, clomiphene citrate, controlled
ovarian stimulation, ovulation induction, intrauterine insemination,
in vitro fertilization, ART and PCOS. Cross-references picked-up
during the review search were also selected if they were not included
initially. Both prospective and retrospective studies were considered.
Studies presented at meetings or congresses, with only abstracts avail-
able, were not included. Variables included were ovulatory cycles,
pregnancy cycle rate and pregnancy patient rate in the letrozole
versus CC in patients with PCOS. In the other groups, the only vari-
able included was the pregnancy rate. Electronic versions of the
retrieved documents were printed. Relevant studies for the analysis
of AIs in PCOS should fulﬁll the following inclusion criteria: (i) letro-
zole as the AI study drug, (ii) randomized-controlled clinical trials
with clomiphene as the comparator drug and (iii) pregnancy rate as
one of the end-points of the trial. Relevant studies for the analysis
of AIs in ovarian stimulation for IUI as well as for IVF should meet
the following inclusion criteria: (i) letrozole as the AI study drug
co-administered with FSH, (ii) randomized and non-randomized
designs, (iii) use FSH alone in the comparator arm and (iv) pregnancy
rate as one of the end-points of the trial.
A pair of two of the authors (M.A.C. and M.F.) independently
assessed every study selected. Doubts were solved by consensus after
Use of letrozole in assisted reproduction
573re-review of the publications. Data entry and statistical analysis was
performed with the use of Review Manager software (RevMan 4.2,
Cochrane Collaboration, Oxford, UK). Meta-analyses of randomized
clinical trials (RCTs) were performed for three comparisons: letrozole
versus CC, letrozole þ FSH versus FSH in IUI and letrozole þ FSH
versus FSH in IVF. In the absence of RCTs, non-randomized studies
were pooled. Heterogeneity was explored by the chi-squared test and
was calculated with the I
2 statistics, a transformation of the Q statistics
thatestimatesthepercentageofthevariationineffectsizesthatisdueto
heterogeneity.Whenheterogeneitywaspresent,theeffectswereexam-
ined using a random effects model. However, when heterogeneity was
notpresent, therandommodelwasalso usedbecause itwasconsidered
amoreconservativeapproach,particularlyifthenumberofstudieswas
small. The common odds ratios with 95% conﬁdence intervals (CI)
were estimated.
Results
Of a total of 37 citations identiﬁed in the initial search, 14 studies
were considered potentially eligible to be included in the review
for one or both authors. During the second phase of the inclusion
process, ﬁve studies were excluded because of lack of fulﬁllment
of the inclusion criteria (3 studies) or considered irrelevant for the
purpose of the review. Finally, nine studies were included with a
total of 2573 women.
Aromatase inhibitors in PCOS
Details of relevant clinical studies of the use of letrozole in women
with PCOS are shown in Table I. In the ﬁrst clinical study of AIs
for ovulation induction, 22 women who had failed to respond to
CC were treated with letrozole. Twelve women with PCOS
received letrozole 2.5 mg daily for 5 days. Ovulation occurred in
75% of patients and pregnancy was achieved in 25% (Mitwally
and Casper, 2001). In another study of CC-resistant women with
PCOS, letrozole induction of ovulation was associated with an
ovulation rate of 54.6% and pregnancy rate of 25% (Elnashar
et al., 2006).
Different studies have assessed the efﬁcacy of AIs for ovulation
induction compared with CC. Findings of four prospective ran-
domized studies deserve to be commented on (Atay et al., 2006;
Bayar et al., 2006; Sohrabvand et al., 2006; Badawy et al.,
2007). In all studies, 2.5 mg letrozole (Atay et al., 2006; Bayar
et al., 2006; Sohrabvand et al., 2006) or 5 mg letrozole (Badawy
et al., 2007) was administered daily for 5 days. Human chorionic
gonadotrophin (hCG) at a dose of 10 000 IU was administered
when at least one follicle with a mean diameter  18 mm was
observed using transvaginal ultrasound. Differences among these
studies are mainly related to the selection of patients. In the
study of Atay et al. (2006), 106 women with oligoamenorrhea
and PCOS were enrolled (55 received CC and 51 letrozole).
Results were more favorable in the letrozole group than in the
CC group regarding the percentage of ovulatory cycles (82.4%
versus 63.6%), pregnancy (21.6% versus 9.1%), monofollicular
cycles (1.2 versus 2.4 follicles  18 mm on the day of hCG admin-
istration) and endometrial thickness (8.4 mm versus 5.2 mm). In
the study of Bayar et al. (2006), 36 patients (95 cycles) were
given CC and 38 patients (95 cycles) were given letrozole. Differ-
ences regarding ovulation rates (74.5% versus 65.7%) or preg-
nancy rates (7.4% versus 9.1%) were not found, although the
percentage of monofollicular cycles was higher in letrozole-
treated women in relation to signiﬁcantly lower estradiol levels
on the day of hCG. In the study of Sohrabvand et al. (2006),
59 women with PCOS resistant to CC were treated with the com-
bination of letrozole and meftormin (53 cycles) or CC and metfor-
min (67 cycles). Differences between the study groups included
higher endometrial thickness in women treated with letrozole
and metformin (8.2 versus 5.5 mm) and higher total estradiol
level on day of hCG administration and mean estradiol level per
mature follicle in the CC group. Recently, Badawy et al. (2007)
studied 438 infertile women (1063 cycles) with PCOS. Patients
were randomized to treatment with 5 mg of letrozole daily (218
Table I. Data of clinical studies of the use of AIs in women with PCOS.
First author,
year
Study design Drug, daily dose Women
no.
Cycles
no.
Mature
follicles or
.15 mm no.
Endometrial
growth (mm)
Ovulatory
cycles (%)
Pregnancy
cycle rate
(%)
Pregnancy
patient rate
(%)
Miscarriage
(%)
Mitwally,
2001
Prospective Letrozole 2.5 mg 12 12 2.1 8.1 75 25 35
Al-Omari,
2004
Prospective,
randomized,
double-blind
Letrozole 2.5 mg 22 22 1.7 8.2 84.4 18.8 27
Anastrazole 1 mg 18 18 2.3 6.5 60.0 9.7 16.6
Atay, 2006 Prospective,
randomized
Letrozole 2.5 mg 51 51 1.2 8.4 82.4 21.6 21.6
Clomiphene 100 mg 55 55 2.4 5.2 63.6 9.1 9.1
Bayar, 2006 Prospective,
randomized,
double-blind
Letrozole 2.5 mg 38 99 1 8 65.7 9.1 21.6 2.6
Clomiphene 100 mg 36 95 1 8 74.7 7.4 19.4 0
Sohrabvand,
2006
Prospective,
randomized,
single-blind
Letrozole
2.5 mg þ metformin
29 53 1.9 8.2 90.6 19 34.5 0
Clomiphene
100 mg þ metformin
30 67 1.8 5.5 80.6 7 16.7 40
Badawy,
2007
Prospective,
randomized
Letrozole 5 mg 218 540 2.3 8.1 67.5 15.1 37.6 12.1
Clomiphene 100 mg 220 523 3.1 9.2 70.9 17.9 42.7 9.7
Elnashar,
2006
Prospective Letrozole 2.5 mg 44 44 1.2 10.2 54.6 13.6 25 0
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574patients, 540 cycles) or 100 mg of CC daily (220 patients, 523
cycles). In this study, advantage to the use of letrozole over CC
as a ﬁrst-line treatment for induction of ovulation in women
with PCOS was not observed as signiﬁcant differences in ovula-
tory cycles, pregnancy rates or miscarriage rates were not found.
In contrast to previous studies, endometrial thickness at the time
of hCG administration was signiﬁcantly greater in the CC group
(9.2 versus 8.1 mm).
One further prospective randomized study used letrozole versus
anastrozole for infertility treatment in women with PCOS. In this
study, 22 women with PCOS were assigned to letrozole (2.5 mg/
day for 5 days) and 18 to anastrozole (1 mg/day for 5 days); in all
patients, hCG was administered to trigger ovulation. The ovulation
rate was signiﬁcantly higher in the letrozole group than in the ana-
strozole group (84.4% versus 60%). Differences in pregnancy
were also signiﬁcant (27% of women in the letrozole group and
16.6% in the anastrozole group) (Al-Omari et al., 2004).
It is remarkable that in none of the aforementioned studies,
hyperstimulation syndrome or multiple gestations were reported.
A meta-analysis including the four randomized-controlled
studies comparing letrozole and clomiphene was done (Atay
et al., 2006; Bayar et al., 2006; Sohrabvand et al., 2006;
Badawy et al., 2007). The overall effects of letrozole in compari-
son with CC in PCOS was neither signiﬁcant for ovulatory cycles
(OR ¼ 1.17; 95% CI 0.66–2.09), nor for pregnancy cycle rate
(OR ¼ 1.47; 95% CI 0.73–2.96) and for pregnancy patient
rate (OR ¼ 1.37; 95% CI 0.70–2.71) (Figs 1 and 2). For all
three outcomes, the I
2 was above 50% indicating that the studies
were not statistically homogeneous.
Aromatase inhibitors plus gonadotrophins in ovarian
stimulation for IUI
In studies published in the literature, there are some discrepancies
regarding the optimal dose of letrozole, timing of gonadotrophin
administration and various aspects related to ovarian and endo-
metrial response.
Al-Fozan et al. (2004) compared the effects of the letrozole
(7.5 mg/day) and CC (100 mg/day) in women undergoing ovu-
lation induction and IUI. The pregnancy rate per cycle was
similar in both groups, but the number of follicles of  14 mm
and of .18 mm was higher in women treated with letrozole. In
the study of Fatemi et al. (2003), 15 patients undergoing IUI
received from Day 3 to Day 7 of the cycle either letrozole
2.5 mg/day (n ¼ 7) or CC 100 mg/day (n ¼ 8). Signiﬁcantly
more follicles ( 17 mm) developed in patients in the CC group
compared with those in the letrozole group. In a retrospective
analysis, Healey et al. (2003) compared FSH alone or a combi-
nation of FSH and letrozole 5 mg/day and also showed that
women co-treated with letrozole developed more follicles
.14 mm. However, the dose of 2.5 mg/day of letrozole associ-
ated with gonadotrophins resulted in a signiﬁcantly lower
number of mature follicles when compared with CC combined
with human menopausal gonadotrophin (hMG) (Jee et al., 2006)
Figure 1: Effect of letrozole on ovulation rate per cycle in PCOS.
Test for heterogeneity: x
2 ¼ 9.54, df ¼ 3( P ¼ 0.02), I
2 ¼ 68.6%. Test for overall effect: Z ¼ 0.53 (P ¼ 0.59).
Figure 2: Effect of letrozole on pregnancy rate per cycle in PCOS.
Test for heterogeneity: x
2 ¼ 8.03, df ¼ 3( P ¼ 0.02), I
2 ¼ 62.7%. Test for overall effect: 1.07 (P ¼ 0.28).
Use of letrozole in assisted reproduction
575and FSH alone (Bedaiwy et al., 2007). These data suggest that to
obtain more moderate ovarian responses, the optimal dose of letro-
zole is 2.5 mg/day on Days 3–7 of the menstrual cycle combined
with gonadotrophins (preferably FSH).
A summary of the results obtained in women with anovulatory
infertility treated with gonadotrophins and those treated with gon-
adotrophins plus letrozole is shown in Table II. Signiﬁcant differ-
ences in pregnancy outcome between the combined regimen of
IAs and FSH versus FSH alone were not observed, although the
use of FSH alone was associated with a higher rate of multiple ges-
tations, particularly in anovulatory women (Mitwally et al., 2005a;
Bedaiwy et al., 2007). In all three studies, a signiﬁcantly lower
FSH dose was used in the letrozole arm. The pooled mean differ-
ence was 691 IU (95% CI 619–764).
A meta-analysis including the above three retrospective studies
comparing letrozole þ FSH versus FSH in ovarian stimulation for
IUI was done (Healey et al., 2003; Mitwally and Casper, 2003;
Bedaiwy et al., 2007). The only variable included was pregnancy
rate per cycle. Meta-analysis procedures were similar to those
described in the PCOS section. The results showed no signiﬁcant
differences in the outcome variable between letrozole þ FSH
versus FSH (OR ¼ 1.15; 95% CI 0.78–1.71) (Fig. 3).
In a recent study, prospective randomized study in 50 couples
with unexplained infertility that failed to conceive after three
cycles of CC combined to IUI, Gregoriou et al. (2007) compared
ovulation induction either with letrozole (5 mg on Days 327o f
the cycle) or recombinant FSH (150 IU every 2 days) combined
to IUI. In this study, signiﬁcant differences in pregnancy rate
per cycle (8.9% in the letrozole group versus 14% in the gonado-
trophin IUI group), cumulative pregnancy rate per couple (24%
versus 36%) and the take home baby rate (20% versus 28%)
were not observed.
Aromatase inhibitors for IVF
There is little information about the use of AIs for IVF because the
number of series published in the literature is small and the
majority of studies are non-randomized. In all studies published
in this area, letrozole was the AI used.
In a prospective randomized pilot study, Verpoest et al. (2006)
showed that response to controlled ovarian stimulation improved
with the use of AIs. In normoresponders undergoing an ovarian
stimulation protocol with recombinant FSH 150 IU and GnRH
antagonist, randomized to receiving letrozole 2.5 mg/day during
the ﬁrst 5 days of stimulation versus no letrozole, a higher
number of oocytes retrieved per cycle was documented in the
letrozole group (14.8 versus 9.6), although differences were not
statistically signiﬁcant. Pregnancy outcome was similar in both
study groups. The use of AIs would allow to correct endometrial
asynchrony produced by controlled ovarian stimulation and to
improve embryo quality by decreasing the incidence of chromo-
some aneuploidies in the oocytes retrieved.
A comparison of data reported in the studies of Goswami et al.
(2004), Garcia-Velasco et al. (2005) and Schoolcraft et al. (2008)
is presented in Table III.
Figure 3: Effect of letrozole on pregnancy rate per cycle in intrauterine insemination.
Test for heterogeneity: x
2 ¼ 0.15, df ¼ 2( P ¼ 0.93), I
2 ¼ 0%. Test for overall effect: Z ¼ 0.70 (P ¼ 0.48).
Table II. Comparison of patients (ovulatory infertility) treated with gonadotrophins and those treated with gonadotrophins plus letrozole in ovarian stimulation
cycles for IUI.
Data Mitwally and Casper (2003) Healey et al. (2003) Bedaiwy et al. (2007)
Letrozole þ FSH FSH Letrozole þ FSH FSH Letrozole þ FSH FSH
Cycles, no. 36 56 60 145 483 125
Days of stimulation 12.5 (1.9) 11.4 (1.4) 7.6 (2) 9.5 (3) 8.4 (1.7) 7.7 (2.2)
FSH dose, IU 465 (309) 1114 (393)* 600 (405) 940 (464)* 394 (355) 1317 (943)*
Mature follicles on hCG day 3 (1.2) 2.7 (1.5) 3.2 (1.2) 2.2 (1.5) 2.61 (1.3) 3.45 (1.7)
Estradiol on hCG day, pmol/l 1540 (877) 3213 (1483)* Not stated Not stated 1604 (1715) 2585 (1792)*
Endometrial thickness on hCG day, mm 9.1 (2) 10 (2) 8.5 (2.6)* 9.4 (1.9) 8.5 (2) 9 (1)
Pregnancy rate, % 22.2 21.4 21.6 20.9 19 16
Multiple pregnancy rate, % Not stated Not stated 0 5 22.5 31.2
Data as mean (SD) unless otherwise stated.
*P , 0.05 between the groups of letrozole þ FSH and FSH alone.
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576Goswami et al. (2004) reported the ﬁrst RCT to assess whether
incorporation of letrozole could be an effective low-cost IVF proto-
col for poor responders. Women over 35 years of age, who had
failedonetothreeIVFattemptsduetopoorovarianresponsetocon-
ventional longGnRH agonist stimulationprotocol, wereselectedfor
this study. A total of 13 participants were randomized to letrozole
2.5 mg/day from Day 3 to Day 7 of the menstrual cycle and sub-
cutaneous rFSH at a dose of 75 IU/d a yo nD a y s3a n d8 ,w h i l e
theremaining25underwentlong GnRH agonist protocolandstimu-
lated with rFSH (300–450 IU/day) (controls). Compared with the
control group, the letrozole–FSH group received a signiﬁcantly
lower total dose of FSH and had signiﬁcantly decreased levels of
terminal E2. The two groups did not differ with respect to the
numbers of matured follicles, retrieved oocytes, transferable
embryos and endometrial thickness. The pregnancy rate/stimulated
cycle was also similar. The authors concluded that adjunctive use of
letrozole may form an effective means of low-cost IVF protocol in
poorly responding women.
Garcia-Velasco et al. (2005) evaluated the use of letrozole as an
adjuvant to FSH treatment in IVF cycles of poor responders. To be
included in the study, patients had to have at least one previous
canceled IVF attempt in which four or fewer follicles 16 mm in
diameter were obtained. Women were divided into a control
group of 76 patients treated with high-dose gonadotrophins in a
GnRH-antagonist regimen, whereas the experimental group of 71
patients received letrozole 2.5 mg plus gonadotrophins for the
ﬁrst 5 days of stimulation followed by the same gonadotrophin/
antagonist regimen. The number of oocytes retrieved, androgens
intrafollicular levels and implantation rates were signiﬁcantly
higher among letrozole-treated patients. Pregnancy rates were also
higher, but differences were not statistically signiﬁcant.
Schoolcraft et al. (2008) have recently reported the results of
a comparison of the efﬁcacy of a microdose GnRH agonist ﬂare
with a GnRH antagonist/letrozole protocol before IVF–embryo
transfer in poor responders. There were no differences in duration
or doses of gonadotrophins required, stimulation days, numbers of
oocytes, percentage of mature oocytes obtained, fecundation rate
and embryo quality. However, ongoing pregnancy rates were
signiﬁcantly lower in the letrozole protocol than in the microdose
GnRH agonist ﬂare protocol (37% versus 52%).
A meta-analysis including two controlled studies (one random-
ized and one non-randomized) comparing letrozole and FSH was
done (Goswami et al., 2004; Garcia-Velasco et al., 2005). The
only variable included was pregnancy rate per patient. Signiﬁcant
differences in the pregnancy rate per patients between both treat-
ment modalities were not found (OR ¼ 1.40; 95% CI 0.6722.91).
Use of letrozole for fertility preservation in oncological patients
The effect of AIs on the production of estrogens has led to their
use in combination with low-dose gonadotrophins to decrease
estrogens levels (Holzer et al., 2006). The combined protocol of
letrozole and low-dose FSH was evaluated in the study of Oktay
et al. (2005). A total of 29 patients underwent 33 ovarian stimu-
lation cycles with either tamoxifen 60 mg/day alone or in combi-
nation with low-dose FSH or letrozole 5 mg in combination with
FSH. After IVF, all resultant embryos were cryopreserved to pre-
serve fertility. Recurrence rates were compared with 31 who
elected not to undergo IVF. A signiﬁcantly greater number of fol-
licles .17 mm, mature oocytes and embryos were observed in
both groups of low-dose FSH combined with either tamoxifen or
letrozole when compared with tamoxifen alone. However, peak
estradiol levels were lower with letrozole þ FSH compared with
tamoxifen þ FSH. Recurrence-free survival analysis did not
show differences between the IVF and the control groups.
In a study of the same group published 1 year later (Oktay et al.,
2006), Stages I–IIIA breast cancer patients (n ¼ 47) received
5m g /day letrozole and 150–300 IU FSH to cryopreserve
embryos or oocytes. Age-matched retrospective controls (n ¼
56) were selected from women who underwent IVF for tubal
disease. Whereas letrozole and FSH stimulation resulted in signiﬁ-
cantly lower peak estradiol levels [mean (SD) 483.4 (278.9) versus
1464.6 (644.9) pg/ml] and 44% reduction in gonadotrophin
requirement, compared with controls, the number of embryos
obtained and fertilization rates were similar. A similar protocol
of letrozole started 2 days before gonadotrophin administration
and then given concomitantly has been successfully applied in
four young patients with endometroid carcinoma undergoing
IVF cycles for immediate or delayed embryo transfer to gesta-
tional carriers before or after staging and deﬁnitive surgery
(Azim and Oktay, 2007).
Safety proﬁle of aromatase inhibitors in ovulation induction
Some studies have shown that anastrozole did not produce terato-
genic effects in animals embryo development; however, there is a
lot of concern related to the inadvertent exposure to letrozole
Table III. Comparison of patients (ovulatory infertility) treated with gonadotrophins and those treated with gonadotrophins plus letrozole in IVF treatment.
Data Goswami et al. (2004) Garcia-Velasco et al. (2005) Schoolcraft et al. (2008)
Letrozole þ FSH FSH Letrozole þ FSH FSH Letrozole þ FSH FSH
Cycles, no. 13 25 71 76 179 355
Days of stimulation Not stated Not stated 9.3 (0.3) 8.9 (0.2) 9.9 (1.3) 10.1 (1.6)
FSH dose, IU 150 (0)* 2865 (/228)* 3627 (116) 3804 (127) 4222 (742) 3937 (975)
Oocytes retrieved 1.6 (0.8) 2.1 (/0.7) 6.1 (0.4) 4.3 (0.3) 12 (6) 13 (5.3)
Estradiol on hCG day, pg/ml 227 (45)* 380 (46)* 770 (67) 813 (60) 1403 (965)** 3147 (1189)**
Pregnancy rate, % 23 24 22.4 15.2 Not stated Not stated
Implantation rate, % Not stated Not stated 25** 9.4** 15 21
Ongoing pregnancy rate, % Not stated Not stated Not stated Not stated 37** 52**
Data as mean (SD) unless otherwise stated.
*P , 0.01 and **P , 0.05 between the groups of letrozole þ FSH and FSH alone.
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577during pregnancy (Tiboni, 2004). The study of Hu et al. (2002)
examined how profound changes in androgen/estrogen ratio
would affect mouse in vitro follicular development. Arimidex, a
potent follicular AI, was used for this purpose. It was found that
a pronounced estrogenic environment is not essential for in vitro
folliculogenesis. Drastic changes in the intrafollicular steroid con-
centrations do not disrupt meiotic maturation nor compromise
early preimplantation development.
The short half-life of AIs and the administration of these drugs
during early follicular phase from Day 3 to Day 7 of the cycle
leave a sufﬁcient interval for complete washout to occur before
fertilization and implantation. In a phase I study performed to
evaluate the safety, pharmacokinetics and pharmacodynamics of
anastrozole, 20 women with regular ovulatory cycles received
single dose of 5, 10, 15 or 20 mg, and 6 received ﬁve daily doses
of 10 or 15 mg (Tredway et al., 2004). The pharmacokinetics of
anastrozole in this study were linear, predictable and consistent
with previously published data from healthy volunteers (Plourde
et al., 1994; Boeddinghaus and Dowsett, 2001). In the single-dose
groups, anastrozole was well and rapidly absorbed, with Cmax
occurring within 2 h. In the multiple-dose groups, the Cmin versus
time proﬁles were consistent with linear kinetics and with a com-
pound with a plasma t1/2 . 30 h. The experiment duration was
insufﬁcient to deﬁnitively evaluate t1/2 and AUC0–1;h o w e v e r ,
the interim parameters AUC0–last and Cmax,a n dCmin and Tmax
were all considered sufﬁcient to meet the study objective and to
conﬁrm the published proﬁle for anastrozole in post-menopausal
women (Boeddinghaus and Dowsett, 2001; Plourde et al., 2004).
On the other hand, in the single-dose groups, E2 levels reached
their nadir 3–6 h after administration, decreasing by an average of
39% from baseline. FSH levels rose by 13%, 52%, 49% and 75%
in the 5, 10, 15 and 20 mg groups, respectively, at  24 h after
dosing. Most subjects recruited just one mature follicle, with no
apparent effect on endometrial maturation. No safety concerns
were noted (Tredway et al., 2004). The development of program
of the drug remains active.
According to the relatively short half-life of AIs ( 45 h), bio-
logical plausibility of the teratogenic effects of AIs when these
drugs are used in the early follicular phase can be rejected.
Nevertheless, if AIs are going to be used for ovulation induc-
tion, measurement of beta-hCG may be recommended to ensure
that candidates to AIs treatment are not pregnant. It is amply
demonstrated that neither CC nor AIs including letrozole should
be administered in pregnant women. Prospective, randomized
studies assessing the potential teratogenic effects of AIs as the
primary end-point have not been conducted. In a cohort study
comparing the outcome of pregnancies achieved after letrozole
and other ovarian stimulation treatments with a control group of
pregnancies spontaneously conceived without ovarian stimulation,
there were 394 pregnancy cycles in 345 infertile couples (63 preg-
nancies with 2.5 mg of letrozole alone or with gonadotrophins, 70
pregnancies with 5.0 mg of letrozole, 113 pregnancies with clomi-
phene alone or with gonadotrophins, 110 pregnancies with gon-
adotrophins alone and 38 pregnancies achieved without ovarian
stimulation). Pregnancies conceived after letrozole treatments
were associated with similar miscarriage and ectopic pregnancy
rates compared with all other groups (Mitwally et al., 2005a).
A small study presented at the 2005 American Society for
Reproductive Medicine meeting suggested that the AI, letrozole,
could cause serious fetal anomalies when used off-label for ovu-
lation induction. In that study, Marinko Biljan, MD, director of
the Montreal Fertility Center, found a malformation rate of 4.7%
among 150 babies born after the use of letrozole, compared with
a rate of just 1.8% in a database of 36 050 normal conceptions.
An identical number of birth defects in each group was reported,
but the incidence of cardiac malformations and malformation of
the musculoskeletal system was signiﬁcantly higher in letrozole-
treated group. As a result, the pharmaceutical company (Novartis),
which markets the drug as Femara for the treatment of breast
cancer, issued global warnings to healthcare professionals about
the potential for letrozole to cause embryo and fetus toxicity in
premenopausal women, and that the drug should only be used
for its primary indication—as breast cancer therapy for post-
menopausal women. That warning was probably premature and
based on a study with several methodological problems. The
main criticism is that the controls were normal deliveries, which
are known to have a lower risk of malformations than babies
born to women needing assistance to ovulate. The mean (standard
deviation, SD) age of women in the letrozole group was 35.2 (4.7)
years compared with 30.5 (1.2) in the control cohort. Moreover,
cardiac and possibly skeletal abnormalities are likely to be diag-
nosed before birth, and the mothers transferred to a tertiary care
hospital for delivery. Therefore, it is possible that such abnormal-
ities were underrepresented in the control cohort. In addition, only
110 women treated with letrozole gave birth to singleton infants,
and it is well known that congenital malformations are more
common in twin births than in singletons.
In a large retrospective study conducted in ﬁve fertility centers in
Canada (Tulandi et al., 2006), the incidence of congenital malfor-
mations among offspring of mothers who conceived with CC
(n ¼ 397) or with letrozole (n ¼ 514) treatment for infertility was
assessed. Overall, congenital malformations and chromosomal
abnormalities were found in 14 of 514 newborns in the letrozole
group (2.4%) and in 19 of 397 newborns in the CC group (4.8%).
The major malformation rate in the letrozole group was 1.2%
(6/514) and in the CC group was 3.0% (12/397). In addition, the
rate of all congenital cardiac anomalies was signiﬁcantly higher
in the CC group (1.8%) compared with the letrozole group (0.2%)
(P ¼ 0.02). On the basis of these data, the concern that letrozole
use for ovulation induction could be teratogenic is unfounded.
Discussion
Medical induction of ovulation using CC is currently a ﬁrst-line
treatment modality in women with WHO type II anovulation
(Eijkemans et al., 2003). The mechanism of action of CC is
related to a negative feedback to the endogenous estrogen, result-
ing in a higher amplitude of gonadotrophin surges, i.e. LH and
FSH. Although CC therapy is associated with a high ovulation
rate (60–80% of patients), less than half women become pregnant,
with a fecundation rate per cycle of 15% in those in which spon-
taneous ovulation has been achieved (Garcia et al., 1977). More-
over, the percentage of ovarian hyperstimulation syndrome and
multiple gestations is low (Hughes et al., 2000). Discrepancies
between ovulation and pregnancy rates as well as the high rate
of miscarriage have been attributed to the negative effect of CC
on the oocyte, the endometrium and the cervical mucus (Kousta
et al., 1997). In the form available for clinical use, CC is a
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578racemic mixture of two stereoisomers, enclomiphene (enC) and
zuclomiphene (zuC), they also have vastly different biological
half-lives in vivo; enC disappears rapidly from the circulation,
whereas zuC is cleared slowly and may accumulate across con-
secutive cycles of treatment. Unintended, adverse, antiestrogenic
effects of CC on the quality and quantity of cervical mucus pro-
duction or endometrial proliferation and maturation have been
related to accumulation of zuC (Young et al., 1999). Morpho-
metric analysis of the endometrium from women with CC-treated
cycles revealed abnormal endometrial development as demon-
strated by a reduction in glandular density and an increase in the
number of vacuolated cells (Sereepapong et al., 2000).
The concept of using AIs for ovulation induction as a new
method that could avoid many of the adverse effects of CC has
recently been explored. Special emphasis has been placed on the
mechanism of action of third-generation AIs compared with CC.
Among the AI group, letrozole is the drug most frequently used
in all published studies so far. Besides the lack of antiestrogenic
effect on the endometrium and cervical mucus, estrogen negative-
feedback is not affected by aromatase inhibition, limited FSH
response can be a protective factor for multiple ovulation and
hyperstimulation syndrome, and accumulation of intraovarian
androgens and up-regulation of estrogen receptors augment fol-
licular sensitivity and favor rapid endometrial growth (Casper
and Mitwally, 2006). Moreover, given the short half-life compared
with CC and the absence of long-lasting antiestrogenic negative
effects, clinical use of AIs may be expected to be associated
with higher pregnancy rates and/or lower miscarriage rates.
The currently available evidence precludes to draw deﬁnite con-
clusions about outcome of the use of AIs for ovulation induction in
PCOS. Methodological limitations are primarily related to the
study design (only four studies were prospective and randomized
and only two of them were masked for observers and/or patients),
small sample sizes, differences in eligibility criteria or sites in
which studies were conducted. All studies agree regarding a
higher percentage of monofollicular cycles in women treated
with AIs compared with CC and, consequently, lower preovula-
tory estradiol concentrations. The studies are consistent in their
ﬁndings of the negative impact of CC on endometrial thickness
compared with IAs. Surprisingly, in the study of Badawy et al.
(2007), endometrial thickness was signiﬁcantly greater in the
CC group than in women given letrozole, which was explained
by the authors to more growing follicles and the higher levels of
estrogen and progesterone in the CC group, although endometrial
thickness in both study groups was .5 or 6 mm. An endometrium
that is thinner than 5–6 mm is usually associated with signiﬁcant
likelihood of failure to conceive (Gonen and Casper, 1990). On the
other hand, in one study which examined cervical mucus, letro-
zole, unlike CC, had no adverse antiestrogenic effect (Elnashar
et al., 2006). Despite all differences between IAs and CC, compar-
able ovulation, pregnancy and miscarriage rates were reported in
the majority of clinical series, suggesting that success obtained
with the use of IAs for ovulation induction in women with
PCOS has been lower than expected. A further consideration of
the costs of each product (IAs are 10 times more expensive)
would probably make CC a more efﬁcient modality of treatment.
Finally, the impact of the administration of 10 000 IU hCG when
at least one follicle with a mean diameter  18 mm is observed in
women treated with antiestrogens is unknown, as well as the effect
of 2.5 or 5 mg doses of letrozole on the differences in the results
obtained. Moreover, whether variations in the established proto-
col, starting the administration of IAs earlier and/or during a
different number of days, may result in better clinical outcomes
are unclear.
Although a major advantage of AIs for ovulation induction in
women with PCOS is mono-ovulation (Casper, 2003), to ensure
multiple ovulation in IUI cycles, addition of a low dose of
FSH to the AI is required. The use of an AI in conjunction with
gonadotrophins reduces the dose of FSH required to achieve
optimum-controlled ovarian stimulation, and this combination
has been found to be more cost-effective than FSH alone
because of the difference of FSH dose and cost (Bedaiwy et al.,
2006; Casper and Mitwally, 2006). In addition, co-treatment
with an AI reduces hyperestrogenism derived from ovarian
stimulation.
On the basis of the pharmacokinetic characteristics of third-
generation AIs, rapidly absorbed after oral administration,
terminated elimination half-life about 48 h, and the absence of
accumulation of metabolites, the use a single dose of letrozole
has been proposed with the aim of achieving maximum estrogenic
suppression during the initial phase of the cycle and absence of
drug metabolites during fertilization and embryogenesis. In a com-
parison of a single dose of letrozole of 20 mg with the standard
dose of 2.5 mg/day for 5 days, similar results were obtained
(Mitwally and Casper, 2001), although more studies are needed
to assess the efﬁcacy of this strategy.
Another interesting aspect of the co-administration of letrozole
and FSH refers to the day of starting FSH injections. It seems that
starting FSH at Day 7 after onset on menses (letrozole is given
from Day 3 to Day 7) is an optimal schedule for a cycle sufﬁciently
large to attain total plasma clearance of letrozole, thus minimizing
the effects of the drug on the endometrium (Casper, 2003;
Mitwally and Casper, 2004). Commencement of FSH treatment
before ending letrozole regimen may cause opposite effects
(Bedaiwy et al., 2007).
There is no evidence of the negative effect of letrozole on
endometrial thickness at the end of the stimulation cycle except
for cases in which the dose of letrozole is higher than 2.5 mg
and gonadotrophins are initiated before termination of AI
treatment.
The ideal regimen of the clinical use of AIs in ovarian stimu-
lation for IUI is the administration of letrozole 2.5 mg/day from
Day 3 to Day 7 plus FSH (100 IU/day) starting on Day 8 after
onset of menses. However, the amount of FSH added to the letro-
zole cycle should be ﬂexible (100 IU/day may be too high in some
young patients and good responders and too little for poor respon-
ders). This schedule favors lower consumption of FSH injections,
a more moderate ovarian responses are obtained (lesser maturefol-
licles and lower levels of estradiol), minimizing the effect of letro-
zole on the endometrium (Healey et al., 2003; Mitwally and
Casper, 2003; Bedaiwy et al., 2007). A recent study has shown
that ovarian stimulation with letrozole was equally effective to
stimulation with gonadotrophins for couples who had failed to
conceive after treatment with CC combined with IUI (Gregoriou
et al., 2007). The increased risk for ovarian hyperstimulation syn-
drome and the risk for multiple gestations, combined to the signiﬁ-
cant cost of the medication, the inconvenience and discomfort
experienced by women taking gonadotrophins therapy, makes
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with IVF.
The role of AIs in ovarian stimulation regimens in assisted
reproduction cycles is controversial. According to lower estradiol
levels associated with the use of AIs, these agents may be indi-
cated to reduce the risk for severe ovarian hyperstimulation syn-
drome. It has been argued that low estradiol concentrations may
be effective to suppress premature LH surge (Mitwally et al.,
2005b). Secondarily, stimulation of the endogenous production
of gonadotrophins through negative feedback mechanisms
reduces the use of exogenous gonadotrophins and, consequently,
the cost of an IVF treatment cycle (Goswami et al., 2004). In
addition, AIs do not deplete estrogenic receptors present in the
hypothalamus–pituitary axis and the endometrium (Casper,
2003; Casper and Mitwally, 2006), and besides stimulation of
endogeneous gonadotrophins, an intrafollicular androgenic
environment induced by AIs (Garcia-Velasco et al., 2005) may
enhance follicular response to FSH by overexpression and sensiti-
zation of FSH follicle receptors (Weil et al., 1998).
All studies done in IVF protocols have been carried out in
patients with poor response to ovarian stimulation. It has been
shown that women with low response to gonadotrophin stimu-
lation exhibited a lower expression of FSH receptor on human
granulosa cells (Thiruppathi et al., 2001). In contrast, women
with ovarian hyperresponse, such as polycystic ovary, show over-
expression of FSH follicular receptors. Given that women treated
with IAs had temporary accumulation of intraovarian androgens
(Webber et al., 2003), it has been postulated that this androgenic
intrafollicular environment may improve response to ovarian
stimulation in low responders. In a prospective pilot study of
low responder patients with a previous canceled IVF cycle
(Garcia-Velasco et al., 2005), adding letrozole for the ﬁrst
5 days of ovarian stimulation in IVF patients, higher levels of
follicular ﬂuid testosterone and androstenedione were observed
in patients who exhibited a signiﬁcantly higher number of
oocytes retrieved as well as a higher implantation rate, hypothesiz-
ing that letrozole may improve the prognosis of these patients.
However, no enhancement of pregnancy rates was noted (Garcia-
Velasco et al., 2005). In another pilot study, Schoolcraft et al.
(2008) compared the efﬁcacy of a microdose GnRH agonist ﬂare
with a GnRH antagonist/letrozole protocol before IVF–ET in
poor responders. The authors concluded that higher ongoing preg-
nancy rates and trend toward superior implantation rates would
suggest that microdose GnRH agonist ﬂare represents a preferred
approach for the poor responder, and attributed the poorer
outcome of the GnRH antagonist/letrozole group to the fact that
letrozole increases follicular ﬂuid androgen levels, which may
have a deleterious effect on oocyte quality. However, methodo-
logical shortcomings of the study, including the inclusion of het-
erogeneous patients and large differences in the treatment
protocols may question that differences encountered may solely
be attributed to the use of letrozole.
Therefore, the effect of letrozole on the low response may be
attributed to two mechanisms: (i) the positive effect that hyperan-
drogenism at the follicular level may have on the FSH receptors
and (ii) the effect of the endogenous secretion of FSH resulting
from aromatase inhibition combined with exogenous adminis-
tration of FSH. In this respect, adjunctive use of letrozole may
form an effective means of low-cost IVF protocol in poorly
responding women (Goswami et al., 2004).
In summary, prospective, randomized, controlled studies are
required to determine the role of letrozole for ovarian stimulation
in IVF both in poor responders as in the framework of low-cost
IVF protocols.
Another additional indication of the use of letrozole has been
ovarian stimulation in patients with cancer to preserve fertility.
Co-adjuvant oncological treatments may have a deleterious
effects on the patient’s fertility, but the incidence of infertility or
subfertility in women undergoing cancer treatment varies and
depends on many factors (i.e. the effects of chemotherapy and radi-
ation therapy depend on the drug or size/location of the radiation
ﬁeld, dose, dose-intensity oral or intravenous method of adminis-
tration, disease, age and pretreatment fertility of the patient). With
the improvement of life expectancy of cancer-treated patients, ferti-
lity preservation is often possible (Lee et al., 2006).
Fertility preservation options for female patients with malig-
nancy include oocyte or embryo cryopreservation before starting
chemotherapy or radiation therapy (Oktay, 2006; Seli and
Tangir, 2005). Success of treatment partially depends on the
number of oocytes retrieved after ovarian stimulation. However,
it should be noted that hypothetically, increasing estradiol levels
may have adverse effects in patients with estrogen-dependent
tumors. Ovarian stimulation with letrozole and FSH appears to
reduce estrogen exposure compared with standard IVF, without
affecting oocyte quality, fecundation rate and the number of
embryos obtained. Even in the case of elevated estrogen levels
after oocyte retrieval, the use of letrozole could be maintained
for some days to obtain reduction of estrogen levels.
The American Society of Clinical Oncology has recently issued
a special article on recommendations for fertility preservation in
cancer patients (Lee et al., 2006). It is emphasized that oncologists
should refer interested and appropriate patients to reproductive
specialists working with institutional review board-approved con-
sents as soon as possible. Some methods of fertility preservation in
females require timing with the menstrual cycle, so expeditious
referrals are suggested to avoid missing opportunities. When refer-
ring patients, however, oncologists should remember that many
methods are still investigational.
Conclusions
At the present time, there is insufﬁcient evidence to establish deﬁ-
nite recommendations on the use of AIs for ovulation induction.
Data of studies already published in the literature should be inter-
preted consideringmethodological limitations related toa few pro-
spective randomized designs, small study populations, differences
in the doses of letrozole, etc. Therefore, large prospective, ran-
domized, controlled trials are necessary to assess the real beneﬁts
offered by letrozole in the treatment of infertility.
(i) In women with PCOS, the percentage of monofollicular
cycles obtained in patients treated with AIs is higher
than in those treated with CC, as a result of which a
lower rate of multiple pregnancies may be expected.
When endometrial thickness was examined, most studies
agree with the negative impact of CC compared with
AIs, except in the study of Badawy et al. (2007) in
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the CC group. Although intra- and interobserver variabil-
ity of the technique may account for the differences, ﬁnd-
ings reported by Badawy et al. should be considered
because this study comprises the largest population to
date. However, results of the meta-analysis showed that
letrozole was not signiﬁcantly superior to CC in the fol-
lowing variables: ovulatory cycles, pregnancy cycle rate
and pregnancy patient rate.
(ii) The recommended regimen in ovarian stimulation for IUI
includes the use of letrozole 2.5 mg/day (from Day 3 to
Day 7 of the cycle) plus FSH (usually 100 IU/day,
although doses can vary depending on the characteristics
of the patients) starting on Day 8. This schedule favors
lower consumption of FSH injections and more moderate
ovarian responses are obtained (lesser mature follicles and
lower levels of estradiol), minimizing the effect of letro-
zole on the endometrium.
(iii) In IVF treatment, letrozole may reduce the requirements
of exogenous gonadotrophins and, consequently, the cost
of an IVF treatment cycle. This is particularly important
in poor responders. In this group of patients, AIs may
have an amplifying effect of the ovarian response. Data
of the meta-analysis showed that letrozole increased preg-
nancy rates, but there was insufﬁcient evidence of a differ-
ence with FSH alone. Further prospective, randomized,
controlled studies are advisable to determine the role of
letrozole for ovarian stimulation in IVF.
(iv) Chemotherapy and radiation therapy, with a deleterious
effect on the patient’s fertility, are frequent modalities of
treatment in oncological patients. The use of letrozole
has been proposed to decrease estradiol levels in cancer-
treated women who want to become pregnant. In patients
with estrogen-dependent breast cancer, the addition of
letrozole 5 mg/day to gonadotrophins in ovarian stimu-
lation protocols decreases signiﬁcantly the levels of estra-
diol without affecting oocyte quality, fecundation rate and
number of embryos obtained.
(v) Cohort studies do not show an increase of congenital mal-
formations among offspring of mothers who conceived
with letrozole treatment for infertility. Because of the
short half-life of AIs, the biological plausibility of the ter-
atogenic effects when these drugs are used in the early fol-
licular phase can be discarded.
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